Hyperfine (NASDAQ:HYPR – Get Free Report) and Nephros (NASDAQ:NEPH – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
Profitability
This table compares Hyperfine and Nephros’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Nephros | 8.38% | 10.60% | 8.05% |
Risk and Volatility
Hyperfine has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Institutional & Insider Ownership
Earnings & Valuation
This table compares Hyperfine and Nephros”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $11.40 million | 6.70 | -$35.57 million | ($0.38) | -1.89 |
| Nephros | $18.79 million | 1.83 | $1.19 million | $0.16 | 19.81 |
Nephros has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Hyperfine and Nephros, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 1 | 2.67 |
| Nephros | 0 | 3 | 1 | 0 | 2.25 |
Hyperfine currently has a consensus price target of $2.02, suggesting a potential upside of 181.25%. Nephros has a consensus price target of $4.00, suggesting a potential upside of 26.18%. Given Hyperfine’s stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than Nephros.
Summary
Nephros beats Hyperfine on 9 of the 15 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
